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A B S T R A C T
Background: Multiple sclerosis (MS) is recognized as the most prevalent chronic inflammatory neurological
disorder diagnosed in young adults. Recent evidence suggests that the T244I polymorphism of the IL7Rα gene
(rs6897932) May influence MS susceptibility; however, individual studies have provided conflicting and con-
troversial results. Therefore, this meta-analysis was conducted to assess the association between the IL7R T244I
polymorphism and the risk of MS.
Method: An extensive search for published literature up to May 2019 was accomplished in the electronic da-
tabases, and 28 studies consisting of 16,260 MS patients and 18,335 controls were included. The pooled odds
ratio (OR) with 95% confidence interval (CI) was calculated to investigate the strength of association.
Results: The results of the present meta-analysis represented significant association between the IL7R T244I
polymorphism and MS susceptibility. (recessive model: OR = 1.126, 95% CI 1.026–1.236, P = .012; dominant
model: OR = 1.172, 95% CI 1.024–1.341, P = .021; homozygous model: OR = 1.213, 95% CI 1.038–1.417,
P= .015; and allelic model: OR = 1.109, 95% CI 1.025–1.200, P= .010, respectively). In the subgroup analysis
according to region, our findings showed significant association in Europe. However, no association was found in
Middle East.
Conclusion: The current meta-analysis demonstrated that the C allele of IL7R T244I polymorphism might be a
risk factor for the MS susceptibility in Europe but not in Middle East.
1. Introduction
Multiple sclerosis (MS) is an autoimmune and neurological disease
characterized by chronic inflammation and neuronal degeneration of
the central nervous system. Over time, this disease can also cause
chronic disability in many patients. MS is the most common nontrau-
matic disabling neurological disease among young adults (Goldberg
et al., 2009), and environmental and genetic factors have been re-
cognized influential on disease susceptibility and severity (Giovannoni
and Ebers, 2007).
Such approaches as candidate gene association, genetic linkage, and
gene expression studies have been employed to discern the genetic basis
of MS (Gregory et al., 2007). Association study is commonly regarded
as a useful strategy to pinpoint genetic risk loci implementing genetic
markers like single nucleotide polymorphisms (SNPs). There is some
evidence of the probable effect of SNPs on the risk of MS development.
Several genetic variants were reported to be associated with the sus-
ceptibility of MS (Jiang et al., 2015; Zhang et al., 2019).
Interleukin 7 receptor (IL7R) is a type I cytokine receptor com-
prising alpha and gamma chain. Generally, IL7Rα can be recognized on
most mature T cells with transient down-regulation upon activation, on
thymocytes, and on immature B cells through the early pre-B stage
(Akkad et al., 2009).
Several SNPs have been identified in IL-7 Rα, including rs6897932,
rs3194051, rs987107, and rs11567686 (Liu et al., 2017). IL7R T244I
(rs6897932) is one of the polymorphisms that has been studied its role
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in the risk of MS. This variant is located in exon 6 of the IL7R gene,
within a transmembrane area of the encoded protein, on chromosome
5p13.8–15. Linkage studies represented that the chromosome 5p12–14
region is closely tied to the risk of MS (Kallio et al., 2009). The IL7R
T244I creates a non-conservative amino acid change on position
244(Ile → Thr) and leads to an increase of skipping of exon six (Teutsch
et al., 2003). IL7R gene includes eight exons, and alternative splicing
generates a soluble isoform lacking exon six (sIL7R) and the functional
effect of lacking exon six on the product of alternatively spliced tran-
scripted of IL7Rα gene, is manifested by changes in the proportion of
the membrane-bound versus soluble isoforms of IL7Rα. Also, a different
regulation of the IL-7 signal transduction pathway follows these
changes (Gregory et al., 2007).
This polymorphism was extensively studied in association with
multiple human traits, and it was reported to influence the risk of some
autoimmune disorders (Vandenbroeck, 2012). Several studies have also
assessed the association of the IL7R T244I Polymorphism and MS sus-
ceptibility, but their results were inconsistent. For instance, Čierny et al.
(Čierny et al., 2015) reported the correlation of MS with IL7R T244I
polymorphism; however, Alsahebfosoul et al. (Alsahebfosoul et al.,
2016) showed no significant association between IL7R T244I poly-
morphism and MS susceptibility.
This meta-analysis study was conducted with more eligible studies
to survey the association between T244I variant of the IL7Rα gene, and
MS susceptibility in two regions so that their significance of an asso-
ciation is investigated more reliably.
2. Methods
2.1. Identification of eligible studies
In line with the objectives of the research, the literature reporting
on the association between the T244I polymorphism of the IL7Rα gene
and MS susceptibility were identified by comprehensive computer-
based searches of PubMed, Scopus, Embase and Google Scholar data-
bases up to May 2019. A combination of the following keywords was
used for the search: “polymorphism” or “SNP” or “variant” and
“Interleukin 7 receptor” OR “IL7R” and “T244I” or “rs6897932” and
“multiple sclerosis” or “MS”. Additional literature was also obtained
from cross-references within both review and original articles. It needs
further mention that no language restrictions were applied.
2.2. Inclusion and exclusion criteria
Studies should have met the following criteria to be included: (1)
published studies; (2) evaluating the association between IL7R T244I
polymorphism and MS risk; (3) original study of human participants (4)
case-control or cohort studies (5) availability of genotype frequency in
the cases and controls (5) meeting Hardy–Weinberg equilibrium (HWE)
by genotype frequencies in the control group of each and every in-
cluded study.
Case reports, review, conference, and duplicate or overlapping
studies were excluded. Furthermore, those studies with no sufficient
data to ascertain the number of genotypes or odds ratio (OR) were
excluded as well.
2.3. Data extraction
The following information was extracted: the author's name, pub-
lication year, the ethnicity of the participants, the sample size of cases
and controls and the number of cases and controls for genotype were
categorized as Caucasian Europe and Middle East poulation.
The two authors checked the results of data extraction to verify their
accuracy, and they reached a consensus on all of them.
2.4. Statistical analysis
The association between IL7R T244I polymorphism and MS sus-
ceptibility was assessed by OR with 95% confidence intervals (95%
CIs), and Z test was implemented to determine the significance of the
pooled OR. Allelic (C vs. T), homozygous (CC vs. TT), heterozygous (CT
vs. TT) dominant (CC + CT vs. TT), and recessive (CC vs. CT + TT)
genetic models were taken into account to check the possible role of
IL7R T244I polymorphism in MS. In addition, subgroup analyses were
stratified by region to gauge the corresponding effect further.
Heterogeneity was measured with Q test and I2 statistics, and this
item was considered significant if I2 > 40% or PQ < 0.1, and the
random-effects model was conducted to calculate the pooled OR.
Otherwise, the fixed-effects model was performed for homogeneous
studies (DerSimonian and Laird, 1986).
The publication bias of all genetic models of IL7R T244I poly-
morphism was examined using the Egger's test and Begg's funnel plots.
P value of> 0.05 in Egger's test shows no publication bias. Also, the
symmetrical shape of the funnel plots represents no evidence of pub-
lication bias among these studies (Song et al., 2002). Furthermore, a
sensitivity analysis was conducted to assess the influence of every single
study on the stability of the results.
It is to be noted that HWE in the control group of every study was
tested with the χ2 test, and P value< .05 was defined as a departure
from HWE. All the statistical analyses were carried out using




The selection process of the studies included in the current meta-
analysis was shown using the PRISMA flow diagram (Fig. 1).
Twenty-eight articles on the association of IL7R T244I poly-
morphism and MS susceptibility were identified (Akkad et al., 2009;
Alcina et al., 2008; Ali-Reza et al., 2017; Alsahebfosoul et al., 2016;
Bashinskaya et al., 2015; Benešová et al., 2018; Bieke Broux et al.,
2010; Čierny et al., 2015; Fang et al., 2011; Gregory et al., 2007; Hafler
et al., 2007; Haj et al., 2015; Heidari et al., 2011; Ibayyan et al., 2014;
Jäger et al., 2013; Kreft et al., 2012; Lundmark et al., 2007; Majdinasab
et al., 2014; O'Doherty et al., 2009; Ramagopalan et al., 2007; Rubio
et al., 2008; Sayad et al., 2017; Shamim et al., 2013; Sombekke et al.,
2011; Svejgaard, 2008; Taheri and Sayad, 2017; Weber et al., 2008;
Zhuang et al., 2015). In three studies, the distribution of the IL7R T244I
polymorphism in healthy controls was inconsistent with HWE, and
these studies were excluded from the current meta-analysis
(Alsahebfosoul et al., 2016; Haj et al., 2015; Zhuang et al., 2015) be-
cause deviation from HWE among controls implies potential bias during
control selection or genotyping errors. On the other hand, three of the
included articles comprised two studies on different populations (Alcina
et al., 2008; Gregory et al., 2007; O'Doherty et al., 2009), therefore,
each one of them is considered as a separate study in this meta-analysis.
Based on the search criteria, 16,260 MS patients and 18,335 con-
trols from 28 eligible studies were retrieved for the current study.
Regarding the region in the 28 available studies. Europe and the Middle
East received 15 and 6 conducted analyses, respectively. The features of
the included studies and final extracted data are represented in Table 1.
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3.2. Quantitative synthesis
The pooled results of all the included studies are indicated in
Table 2. The analysis indicated a significant association between IL7R
T244I polymorphism and MS risk in four genetic models (recessive
model: OR = 1.126, 95% CI: 1.026–1.236, P = .012; dominant model:
OR = 1.172, 95% CI: 1.024–1.341, P = .021; homozygous model:
OR = 1.213, 95% CI: 1.038–1.417, P = .015; and allelic model:
OR = 1.109, 95% CI: 1.025–1.200, P = .010, respectively) but no
significant association was found using a Heterozygous model
(OR = 1.080, 95% CI: 0.987–1.182, P = .093) (Fig. 2).
Also, in stratified analysis of regions, the same results were obtained
in Europe (recessive model: OR = 1.216, 95% CI: 1.121–1.318,
P < .001; dominant model: OR = 1.271, 95% CI: 1.135–1.423,
P < .001; homozygous model: OR = 1.347, 95% CI: 1.200–1.511,
P < .001; and allelic model: OR = 1.180, 95% CI: 1.103–1.263,
P < .001, respectively). In addition, significant association was re-
vealed in heterozygous model in Europe population (OR = 1.130, 95%
CI: 1.004–1.271, P = .042). In contrast, the analysis of the Middle East
population showed no significant association between IL7R T244I
polymorphism and the risk of MS under all five genetic models (Fig. 3).
3.3. Test of heterogeneity, sensitivity analysis and publication bias
Thompson and Higgins classification index (I2) and chi-square
based Q statistic test was utilized to investigate the heterogeneity
among the studies and significant heterogeneity was observed in the
recessive (PQ < 0.001; I2 = 71.51%), the dominant (PQ = 0.006;
I2 = 45.08%), the homozygous (PQ < 0.001; I2 = 55.78%), and the
allelic model (PQ < 0.001; I2 = 74.41%). Therefore, the random-
effect model was implemented to calculate CIs. In contrast, the het-
erozygous model (PQ = 0.282; I2 = 12.14%) did not display sig-
nificant heterogeneity, so ORs were pooled according to the fixed-ef-
fects model. Furthermore, the results of the heterogeneity test in
subgroup analysis were shown in Table 2.
Sensitivity analyses were carried out excluding each study in turn to
reflect the influence of individual study on pooled OR in all of the five
models. When other studies remained in the analysis with the exclusion
of one study, overall results underwent no significant changes. Then It
was concluded that the results obtained from all of the models were
highly reliable (Fig. 4).
Begg's funnel plot and Egger's test were conducted to assess the
publication bias in both overall and subgroup analyses in the present
meta-analysis, and no obvious asymmetry has been observed in the
Fig. 1. PRISMA Flow diagram of the study selection process.
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shape of the funnel plots in all genetic models (Fig. 5). In addition, the
results of Egger's test showed no evidence of publication bias in both
overall and stratified analyses under all genetic models (Table 2).
4. Discussion
Thrent meta-analysis was conducted to assess the association of
T244I polymorphism of the IL7Rα gene with MS susceptibility. The
results represented that the C allele of IL7R T244I polymorphism has a
Table 1
The main characteristics of case-control studies on association between the IL7R T244I polymorphism and multiple sclerosis susceptibility.
First author (year) Country Ethnicity Genotype distribution in control subjects Genotype distribution in MS patients PHWE in controls
CC CT TT Total CC CT TT Total
Ramagopalan et al. (2007) Canada Caucasian 602 491 100 1193 783 639 131 1553 0.97
Gregory et al. (2007) USA Mixed 265 156 17 438 256 192 31 479 0.53
Gregory et al. (2007) UK and Belgium Caucasian 622 396 59 1077 1412 1087 226 2725 0.41
Lundmark et al. (2007) Nordic Caucasian 642 423 82 1147 595 500 115 1210 0.5
Hafler et al. (2007) UK and US Mixed 1306 871 145 2322 1680 1120 187 2987 0.98
Weber et al. (2008) Germany Caucasian 115 78 13 206 337 229 39 605 0.31
Rubio et al. (2008) Australia Mixed 640 424 70 1134 727 464 74 1265 0.45
O'Doherty et al. (2009) USA Mixed 124 72 11 207 201 174 38 413 0.96
O'Doherty et al. (2009) UK Caucasian 257 176 30 463 287 206 37 530 0.42
Alcina et al. (2008) Spain Caucasian 365 202 32 590 304 254 36 594 0.07
Alcina et al. (2008) Sweden Caucasian 593 508 109 1210 605 518 111 1234 0.29
Svejgaard (2008) Nordic Caucasian 642 423 83 1148 595 500 115 1210 0.5
Akkad et al. (2009) Germany Caucasian 719 465 83 1267 456 346 66 868 0.97
Broux et al. (2010) Belgium Caucasian 35 27 3 65 16 16 1 33 0.2
Heidari et al. (2011) Iran Asian 61 37 2 100 64 29 7 100 0.15
Sombekke et al. (2011) Netherlands Caucasian 407 244 46 697 80 76 18 174 0.99
Fang et al. (2011) Japan Asian 147 40 0 187 100 52 6 158 0.81
Kreft et al. (2012) Netherlands Caucasian 66 55 9 130 35 32 9 76 0.68
Jäger et al. (2013) Germany Caucasian 290 160 34 484 161 133 16 310 0.31
Shamim et al. (2013) USA Caucasian 311 224 52 587 319 221 43 583 0.58
Majdinasab et al. (2014) Iran Asian 66 51 5 127 73 26 5 109 0.2
Ibayyan et al. (2014) Jordan Asian 134 60 6 200 133 64 3 200 0.13
Čierny et al. (2015) Slovakia Caucasian 162 94 14 270 164 110 29 303 0.1
Sadeghi Haj et al. (2015) Iran Asian 129 79 2 210 159 86 1 246 0.003a
Bashinskaya et al. (2015) Russia Caucasian 307 178 24 509 173 94 9 276 0.38
Zhuang et al. (2015) China Asian 111 45 3 159 329 134 5 468 0.031a
Alsahebfosoul et al. (2016) Iran Asian 148 52 0 200 142 58 0 200 0.016a
Sayad et al. (2017) Iran Asian 53 34 13 100 66 29 5 100 0.45
Ahmadi (2017) Iran Asian 17 12 1 30 7 20 3 30 0.36
Taheri and Sayad (2017) Iran Asian 38 26 11 75 63 10 2 75 0.07
Benešová et al. (2018) Czech Caucasian 171 115 11 297 76 47 12 135 0.24
HWE: Hardy-Weinberg equilibrium.
a Deviated from HWE (excluded studies).
Table 2
The association of IL7R T244I polymorphism with multiple sclerosis risk.
Genetic model Number of studies Test of heterogeneity Test of association PEgger’s test
OR 95% CI POR PQ-test I2 Model
Overall
C vs. T 28 1.109 1.025–1.200 0.01 <0.001 74.41 Ra 0.994
CC vs. TT 28 1.213 1.038–1.417 0.015 <0.001 55.78 R 0.717
CT vs. TT 28 1.08 0.987–1.182 0.093 0.282 12.14 Fb 0.477
CC + CT vs. TT 28 1.172 1.024–1.341 0.021 0.006 45.08 R 0.645
CC vs. CT + TT 28 1.126 1.026–1.236 0.012 <0.001 71.51 R 0.973
Europe
C vs. T 15 1.18 1.103–1.263 < 0.001 0.032 44.51 R 0.944
CC vs. TT 15 1.347 1.200–1.511 < 0.001 0.143 28.61 F 0.878
CT vs. TT 15 1.13 1.004–1.271 0.042 0.325 11.45 F 0.901
CC + CT vs. TT 15 1.271 1.135–1.423 < 0.001 0.193 23.53 F 0.985
CC vs. CT + TT 15 1.216 1.121–1.318 < 0.001 0.06 39.16 R 0.893
Middle East
C vs. T 5 0.764 0.471–1.238 0.275 <0.001 82.37 R 0.942
CC vs. TT 5 0.717 0.252–2.039 0.532 0.011 66.39 R 0.241
CT vs. TT 5 0.927 0.506–1.699 0.807 0.153 37.93 F 0.444
CC + CT vs. TT 5 0.762 0.315–1.844 0.546 0.03 59.67 R 0.734
CC vs. CT + TT 5 0.734 0.417–1.292 0.284 <0.001 80.78 R 0.929
a Random-effect model.
b Fixed-effect model.
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significant association with increased MS risk in Europe. Also, Cierny
et al. suggested T allele and TT genotype protect against the rapid
disability progression in MS (Čierny et al., 2015).
IL7R is a receptor that comprises two different protein chains (alpha
and gamma chain that also known as CD127 and CD132 respectively),
and the function of IL-7, as the ligand of IL7R, is mediated by binding to
IL7Rα of the IL-7 receptor (Fry and Mackall, 2002).
The regulation of T cell homeostasis, survival, and proliferation of
memory and naive T cells is mediated by IL-7 in the periphery (Surh
and Sprent, 2008). In addition, the function and development of lym-
phoid tissue inducer cells are dependent on IL-7 signals. Also, It has
recently been represented that IL-7 affects histone acetylation through
STAT5 in order to regulate the accessibility of the TCR γ locus
(Vandenbroeck, 2012).
The interaction between IL-7 and IL7R forms a complex which is
vital to multiple signaling cascades involved in the proliferation and
survival of T cells, one of which is autoreactive T-cell clones. The IL-7/
IL7R pathway has been suggested to be influential in the autoimmunity
and alloimmunity expansion (Monti et al., 2008). Chen et al. reported
IL-7 is the key cytokine driving the differentiation and proliferation of
thymic Foxp3+ T regulatory cells in Experimental autoimmune en-
cephalomyelitis (EAE), which efficiently ameliorate EAE (Chen et al.,
2009).
It needs further mention that the activation of myelin reactive T
cells has proved to be influential in the onset of MS. These auto-reactive
T cells in MS patients seem to be skewed towards a pro-inflammatory
Th1 phenotype with IL-7, which is regarded as a feasible determining
factor for the stimulation and expansion of these cells in response to
Fig. 2. Forest plot of associations between IL7R T244I polymorphism and multiple sclerosis susceptibility (a) Homozygous model (CC vs. TT) (b) Recessive model (CC
vs. CT + TT).
Fig. 3. Forest plot of subgroup analysis by region on the association between IL7R T244I polymorphism and multiple sclerosis risk (a) Dominant model of (CC + CT
vs. TT) (b) Allelic model (C vs. T).
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antigens (Stinissen and Hellings, 2008).
Alteration of IL7Ra gene expression can influence pathways in-
volved in MS development. C allele in the rs6897932 polymorphism
results in a rise in the skipping of exon six, which leads to the formation
of a soluble form of IL7R. The transmembrane domain (exon six) is
absent in the soluble isoform of the receptor (Rose et al., 2009) and
eventually causes a reduction in IL7Rα expression on T cells (Broux
et al., 2010). A decrease in IL-7 binding might result from the decrease
in IL7R, which leads to the growth of IL-7 level in serum accordingly.
Furthermore, it was illustrated that IL-7 improves T-cell response to
myelin proteins (Gregory et al., 2007). IL-7 augmented concentrations
are found postislet transplantation and are closely related to homeo-
static increased formation of T cells (Monti et al., 2008). There was also
another augmentation revealed in the synovial fluid of patients who
suffer from rheumatoid arthritis, which was related to IL-7 concentra-
tions (Hartgring et al., 2009), in the cerebrospinal fluid and serum of
patients with multiple sclerosis (Lundmark et al., 2007). Furthermore,
IL-7 was significantly decreased in multiple sclerosis patients at relapse
compared with patients with spinocerebellar degeneration (SCD)
(Ishizu et al., 2005).
There are some limitations to the present meta-analysis. Firstly,
stratified analyses require a larger sample size and this study was based
on unadjusted risk estimates, since information related to influential
factors on the estimates of associations like age, sex, smoking, alcohol
consumption, family background, etc. were not available in most of the
included studies. Secondly, potential gene-gene and gene-environment
interactions were not analyzed due to a lack of relevant data. Finally,
only one polymorphism of the IL7Ra gene was evaluated in the current
study, and it is to be noted that interaction between polymorphisms in
the same gene may change the OR values.
The current meta-analysis also had its own advantages. In com-
parison with the previous meta-analyses (Tavakolpour, 2016; Wu et al.,
2016; R. Zhang et al., 2011), the present study consists of more relevant
studies and the analysis was performed on five genetic models. In ad-
dition, genetic distribution and the region of the population which
demonstrated in Table 1 are more accurate and reliable. Furthermore,
in this meta-analysis, the polymorphism of interest was evaluated in
both Europe and Middle East. Also, no evidence of publication bias was
detected, and the sensitivity analysis indicated the reliability and ro-
bustness of the results.
5. Conclusion
In summary, this meta-analysis was accomplished to examine the
association of T244I polymorphism of the IL7Ra gene with MS risk. Our
findings represented that the C allele of IL7R T244I polymorphism has a
significant association with increased MS susceptibility in the Europe
population. More association studies with larger sample sizes in various
ethnicities and regions are required to confirm genetic variants and
assess the functional effect of this polymorphism on MS risk.
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